R. Lapenta
R. Lapenta publishes mostly in Surgery, Oncology and Pulmonary and Respiratory Medicine, on topics such as Esophageal and GI Pathology, Genetic factors in colorectal cancer and Pancreatic and Hepatic Oncology Research.
- World rank
- #6,495,033 of 7,710,434 ranked researchers
- Rank in Malaysia
- #34,479 of 41,196
- Works
- 35
- Citations
- 169
- Citations per work
- 4.8
What does R. Lapenta research?
R. Lapenta's work is mostly in Medicine (76%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2775.9%
- Medicine2775.9%
- Everything else824.1%
- 1Surgery30% of their works
- 2Oncology14% of their works
- 3Pulmonary and Respiratory Medicine14% of their works
- 4Pathology and Forensic Medicine8% of their works
- 5Epidemiology5% of their works
- 6Gastroenterology4% of their works
Research topics
- Esophageal and GI Pathology
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
Which keywords describe R. Lapenta's research?
The keywords of their largest research topics: Chemotherapy, Molecular Characterization, Adjuvant Chemotherapy, Clinical Practice Guidelines, Endoscopic Stenting, Esophageal Perforation, Neoadjuvant Therapy and Hereditary Syndromes.
- Rectal Cancer
- KRAS Mutations
- Cetuximab
- Pancreatic Cancer
- Lung Tumors
- Endoscopic Resection
- Hereditary Syndromes
- Esophageal Perforation
- Clinical Practice Guidelines
- Molecular Characterization
- Chemotherapy
- Adjuvant Chemotherapy
- Endoscopic Stenting
- Neoadjuvant Therapy
- Microsatellite Instability
- Gastric Cancer
- Metastatic Carcinomas
- Surgical Complications
- Imatinib Mesylate
- Preoperative Chemoradiotherapy
- Sunitinib
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 21 words, with their numbers
- Chemotherapy113 topics
- Molecular Characterization92 topics
- Adjuvant Chemotherapy82 topics
- Clinical Practice Guidelines72 topics
- Endoscopic Stenting71 topic
- Esophageal Perforation71 topic
- Neoadjuvant Therapy72 topics
- Hereditary Syndromes51 topic
- Microsatellite Instability51 topic
- Endoscopic Resection41 topic
- Gastric Cancer41 topic
- Lung Tumors41 topic
- Metastatic Carcinomas41 topic
- Pancreatic Cancer41 topic
- Surgical Complications41 topic
- Cetuximab31 topic
- Imatinib Mesylate31 topic
- KRAS Mutations31 topic
- Preoperative Chemoradiotherapy31 topic
- Rectal Cancer31 topic
- Sunitinib31 topic
Where does R. Lapenta work?
R. Lapenta's main affiliation in the publication record is National Cancer Institute, Malaysia.
How many publications and citations does R. Lapenta have?
OpenAlex counts 35 works and 169 citations for R. Lapenta, an h-index of 6, ranking #6,495,033 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about R. Lapenta. Posts are plain text and can be reported.